Last reviewed · How we verify

Clobex TM 0.05% Lotion, single exposure

Actavis Inc. · Phase 1 active Small molecule Quality 0/100

Clobex TM 0.05% Lotion, single exposure is a Small molecule drug developed by Actavis Inc.. It is currently in Phase 1 development. Also known as: Clobetasol.

At a glance

Generic nameClobex TM 0.05% Lotion, single exposure
Also known asClobetasol
SponsorActavis Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Clobex TM 0.05% Lotion, single exposure

What is Clobex TM 0.05% Lotion, single exposure?

Clobex TM 0.05% Lotion, single exposure is a Small molecule drug developed by Actavis Inc..

Who makes Clobex TM 0.05% Lotion, single exposure?

Clobex TM 0.05% Lotion, single exposure is developed by Actavis Inc. (see full Actavis Inc. pipeline at /company/actavis-inc).

Is Clobex TM 0.05% Lotion, single exposure also known as anything else?

Clobex TM 0.05% Lotion, single exposure is also known as Clobetasol.

What development phase is Clobex TM 0.05% Lotion, single exposure in?

Clobex TM 0.05% Lotion, single exposure is in Phase 1.

Related